

DAFTAR PUSTAKA

- Abdollahi, A., Tabatabaee, M., Aghazadeh Amiri, M., & Mafi, A. (2022). Refractive error and visual acuity changes following systemic chemotherapy. *Current Research in Medical Sciences*, 6(1), 1–9.
- Adhikari, S., Dongol, R. M., Hewett, Y., & Shah, B. K. (2014). Vincristine-induced blindness: a case report and review of literature. *Anticancer Research*, 34(11), 6731-6733.
- Adriano, L., Persona, E. L. de S., Persona, I. G. de S., Pontelli, R. C. N., & Rocha, E. M. (2021). Correlation between the presumed pterygium with dry eye and with systemic and ocular risk factors. *Arquivos Brasileiros de Oftalmologia*, 85, 136–143.
- Anderson, D. E., Holstein, S. A., & Kedar, S. (2020). Visual Pathway Degeneration in Chemotherapy-Related Neurotoxicity: A Review and Directions for Future Research. *Neuro-ophthalmology* (Aeolus Press), 44(3), 139–147.
- Ayaki, M., Negishi, K., Kawashima, M., Uchino, M., Kaido, M., & Tsubota, K. (2020). Age Is a Determining Factor of Dry Eye-Related Signs and Symptoms. *Diagnostics*, 10(4), 193.
<https://doi.org/10.3390/diagnostics10040193>
- Barcsay-Veres, A., Tokes, A. M., Toth, J., Szilagyi, Z., Toth, E. K. (2022) Novel Meibomian Gland and Tarsal Conjunctival Changes Associated with Trastuzumab, Pertuzumab, and Anastrozole Treatment for Metastatic HER2 Positive Breast Cancer: A Case Report and Literature Review. *Case Reports in Oncology*, 5, 486–493
- Basile, D., Di Nardo, P., Corvaja, C., Garattini, S. K., Pelizzari, G., Lisanti, C., Bortot, L., Da Ros, L., Bartoletti, M., Borghi, M., Gerratana, L., Lombardi, D., & Puglisi, F. (2019). Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. *Cancers*, 11(6), 857.
- E, Indelicato DJ, Morris CG, Rotondo RL, Bradley JA. Visual decline in pediatric survivors of brain tumors following radiotherapy. *Acta Oncol.* 2020 Oct 2;59(10):1257–62.



- Berry, S. R., Cosby, R., Asmis, T. R., Chan, K. K., Hammad, N., & Krzyzanowska, M. K. (2013). Randomized controlled trials (RCTs) examining continuous (CS) versus intermittent strategies (IS) of delivering systemic treatment (Tx) for untreated metastatic colorectal cancer (mCRC): A meta-analysis from the Cancer Care Ontario program in evidence-based care.
- Caley, A., & Jones, R. (2012). The principles of cancer treatment by chemotherapy. *Surgery (Oxford)*, 30(4), 186-190.
- Camp DA, Lally SE, Shields CL. Heterochromia following intravitreal chemotherapy in two cases. *J Am Assoc Pediatr Ophthalmol Strabismus*. 2019 Aug;23(4):241–3.
- Candido dos Reis, F. J., Wishart, G. C., Dicks, E. M., Greenberg, D., Rashbass, J., Schmidt, M. K., ... & Pharoah, P. D. (2017). An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. *Breast Cancer Research*, 19(1), 1-13.
- Chadha N, Silakari O. Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view. *European Journal of Medicinal Chemistry*. 2017 Jul 7;134:159-84.
- Chiang, J. C. B., Zahari, I., Markoulli, M., Krishnan, A. V., Park, S. B., Semmler, A., Goldstein, D., & Edwards, K. (2020). The impact of anticancer drugs on the ocular surface. *The Ocular Surface*, 18(3), 403–417.
- Chowdary, C. C., Sunanda, V., & Reddy, Y. J. (2018). Study of changes in serum electrolytes and its risk in development of senile cortical cataract. *Journal of Evolution of Medical and Dental Sciences*, 7(27), 3115–3119.
- Cohen V. M. (2013). Ocular metastases. *Eye (London, England)*, 27(2), 137–141.
- Dai, J., Belum, V. R., Wu, S., Sibaud, V., & Lacouture, M. E. (2017). Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. *Journal of the American Academy of Dermatology*, 77(5), 902–910.e2.
- U. F., McGeechan, K., Jenkins, M. C., Barratt, A., Tattersall, M. H., & Wilcken, N. (2013). Combination versus sequential single agent



chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews, (12).

Dearden, C. E., Else, M., & Catovsky, D. (2011). Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. *Leukemia & lymphoma*, 52(sup2), 21-24.

Desbats, M. A., Giacomini, I., Prayer-Galetti, T., & Montopoli, M. (2020). Metabolic plasticity in chemotherapy resistance. *Frontiers in oncology*, 10, 281.

Dickens, E., & Ahmed, S. (2018). Principles of cancer treatment by chemotherapy. *Surgery (Oxford)*, 36(3), 134-138.

Dorff, T. B., & Sweeney, C. J. (2017). Chemotherapy for oligometastatic prostate cancer. *Current opinion in urology*, 27(6), 553-558.

Dubas, K., Buczkowska, H., Michalski, A., & Mardas, M. (2023). Management of diplopia due to chemotherapy toxicity in a patient with endometrial cancer. *Clinical and Experimental Optometry*, 1–3.

Einarsson, E.-J., Patel, M., Petersen, H., Wiebe, T., Fransson, P.-A., Magnusson, M., & Moëll, C. (2018). Elevated visual dependency in young adults after chemotherapy in childhood. *PLOS ONE*, 13(2), e0193075. <https://doi.org/10.1371/journal.pone.0193075>

Ejimađu, S. (2019). Relationship between Intra Ocular Pressure and Visual Acuity in Port Harcourt, Nigeria. *World Journal of Ophthalmology & Vision Research*, 2(1). <https://doi.org/10.33552/WJOVR.2019.02.000529>

Esmer, O., Karadag, R., Soylu, E., Oner, A. F., & Burakgazi-Dalkilic, E. (2013). Nasolacrimal system obstruction, ptosis and esotropia due to chemotherapy in acute lymphoblastic leukemia. *Cutaneous and Ocular Toxicology*, 32(4), 330-332.



ini, G., Cameli, N., Romano, M. C., Mariano, M., Panariello, L., Bianca, D., & Monfrecola, G. (2012). Chemotherapy and skin reactions. *Journal of experimental & clinical cancer research : CR*, 31(1), 50.

K, Drimtzias E, Picton S, Simmons I. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis

type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort. *Br J Ophthalmol.* 2018 Oct;102(10):1367–71.

Fortes BH, Tailor PD, Dalvin LA. Ocular toxicity of targeted anticancer agents. *Drugs.* 2021;81(7):771–823.

Fortes, B. H., Liou, H., & Dalvin, L. A. (2022). Ophthalmic adverse effects of taxanes: The Mayo Clinic experience. *European Journal of Ophthalmology*, 32(1), 602–611. <https://doi.org/10.1177/1120672120969045>

Glimelius, I., & Diepstra, A. (2017). Novel treatment concepts in Hodgkin lymphoma. *Journal of internal medicine*, 281(3), 247-260.

Goldstein, M., & Kastan, M. B. (2015). The DNA damage response: implications for tumor responses to radiation and chemotherapy. *Annual review of medicine*, 66, 129-143.

Grewal, D. S., Holland, P. M., Frankfurt, O., & Pyatetsky, D. (2014). Asymmetric Anterior Uveitis as a Delayed Complication of Treatment with Systemic High-dose Cytosine–Arabinoside: A Case Report and Literature Review. *Ocular Immunology and Inflammation*, 22(4), 322-325.

Gondhowiardjo, S., Christina, N., Ganapati, N.P.D. (2021). Five Year Cancer Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia. *Global Oncology*, 7,190-203.

Guthoff, T., Tietze, B., Meinhardt, B., Becher, J., & Guthoff, R. (2010). Cytosine-arabioside-induced keratopathy: a model of corneal proliferation kinetics. *Ophthalmologica*, 224(5), 308-311.

Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S. E., ... & Stintzing, S. (2014). FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *The lancet oncology*, 15(10), 1065-1075.

, S. H., Maffofou Nkenyi, L. N., Singh, N. U., Yalzadeh, D., Ngele, K. K., Njie-Mbye, Y.-F., Ohia, S. E., & Opere, C. A. (2020). Current trends in the pharmacotherapy of cataracts. *Pharmaceuticals*, 13(1), 15.



- Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?. *Acta Ophthalmologica*. 2013 Nov;91(7):604-9.
- Huang, Y. C., Wang, C. J., & Jou, J. R. (2019). Blindness due to leptomeningeal carcinomatosis as an initial manifestation of recurrent acute lymphoblastic leukemia. *Taiwan Journal of Ophthalmology*, 9(4), 288.
- Jonas JB, Budde WM, Stroux A, Oberacher-Velten IM, Juenemann AG. Circadian intraocular pressure profiles in chronic open angle glaucomas. *J Ophthalmic Vis Res*. 2010;5(2):92–100.
- Kaida, T., Ogawa, T., & Amemiya, T. (1999). Cataract induced by short-term administration of large doses of busulfan: a case report. *Ophthalmologica*, 213(6), 397-399.
- Kalra, R., Chavada, B., Madhani, N. R., Purohit, B., & Tripathi, C. B. (2018). Cyclophosphamide and/or anthracyclines induced Epiphora in breast cancer patients: a rare side-effect. *Current Drug Safety*, 13(1), 62-64.
- Kam, K. W., Di Zazzo, A., De Gregorio, C., Narang, P., Jhanji, V., & Basu, S. (2023). A review on drug-induced dry eye disease. *Indian Journal of Ophthalmology*, 71(4), 1263–1269.
- Karamitsos, A., Kokkas, V., Goulas, A., Paraskevopoulos, P., Gougoulas, K., Karampatakis, V., & Boboridis, K. (2013). Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen. *Hippokratia*, 17(2), 120.
- Karl MD, Francis JH, Iyer S, Marr B, Abramson DH. Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma With Vitreous Seeding. *J Pediatr Ophthalmol Strabismus*. 2017 May;54(3):185–90.
- fard G, Cheraghi H, Aryaei Tabar H. Effect of vincristine on intraocular pressure and tear fluid oxidative stress biomarkers in canine transmissible venereal tumor. *Vet Ophthalmol*. 2023 May 29;vop.13108.



- Khatan, N.I.O., Sani, D., Kirby, B.P., Muhtaruddin, N., Fuang, H.G., Basri, H., Stanslas., J. (2019). Cancer incidence and chemotherapy-induced adverse effects in Asia. *International Journal of Care Scholars*, 2(1), 4-12.
- Kim, Y. W., & Park, K. H. (2019). Exogenous influences on intraocular pressure. *British Journal of Ophthalmology*, 103(9), 1209–1216. <https://doi.org/10.1136/bjophthalmol-2018-313381>
- Koç İ, Taylan Şekeroğlu H, Kıratlı H, Lotfisadigh S. Management of cataracts secondary to intravitreal chemotherapy injections for retinoblastoma seeding. *Eur J Ophthalmol*. 2022 May;32(3):1766–71.
- Krema, H., Santiago, R. A., Schuh, A., & Pavlin, C. J. (2013). Cytarabine toxicity of the corneal endothelium. *Annals of hematology*, 92(4), 559-560.
- Kunkler, A. L., Binkley, E. M., Mantopoulos, D., Hendershot, A. J., Ohr, M. P., Kendra, K. L., ... & Cebulla, C. M. (2019). Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. *Graefe's Archive for Clinical and Experimental Ophthalmology*, 257(8), 1771-1781.
- Laviano, A., & Rossi Fanelli, F. (2012). Toxicity in chemotherapy—when less is more. *New England Journal of Medicine*, 366(24), 2319-2320.
- Lee, H., Yoon, S., & Baek, S. (2023). Causes of Tearing in Patients With Chemotherapy: Meibomian Gland Dysfunction Versus Lacrimal Drainage Obstruction. *Journal of Craniofacial Surgery*, 34(5), e419–e423.
- Lee, M. S., McKinney, A. M., Brace, J. R., & SantaCruz, K. (2010). Clinical and imaging features of fludarabine neurotoxicity. *Journal of Neuro-Ophthalmology*, 30(1), 37-41.
- Lee, V., Bentley, C. R., & Olver, J. M. (1998). Sclerosing canalculitis after 5-fluorouracil breast cancer chemotherapy. *Eye*, 12(3), 343-349.
- . H., You, S. K., & Lee, Y. H. (2021). Bilateral optic neuropathy following vincristine chemotherapy: A case report with description of multimodal imaging findings. *Medicine*, 100(9).



- Lin K, Lee S, Liu S, Tsao C, Hsu S, Chien W, et al. Risk of ocular complications following radiation therapy in patients with nasopharyngeal carcinoma. *The Laryngoscope*. 2020;130(5):1270–7.
- Liu CY, Francis JH, Brodie SE, Marr B, Pulido JS, Marmor MF, Abramson DH. Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. *Retina*. 2014 Jul 1;34(7):1261-80.
- Lockwood A, Mitchell A, Lewis K, Papadopoulos M, Gray J, May K. Dexamethasone induced glaucoma as part of chemotherapy for lymphoblastic lymphoma and colorectal cancer. *Acta Ophthalmol (Copenh)*. 2016 Oct;94(S256):j.1755-3768.2016.0594.
- M McQuade, R., Stojanovska, V., C Bornstein, J., & Nurgali, K. (2017). Colorectal cancer chemotherapy: the evolution of treatment and new approaches. *Current medicinal chemistry*, 24(15), 1537-1557.
- Ma J, Pazo EE, Zou Z, Jin F. Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional study. *The Breast*. 2020 Oct;53:164–71.
- Machairoudia G, Kazantzis D, Chatziralli I, Kampoli K, Ntavatzikos A, Theodossiadis P, et al. Prevalence and risk factors of dry eye disease in patients treated with aromatase inhibitors for breast cancer. *Clin Exp Optom*. 2023 Sep 12;1–5.
- Maleki, A., Lagrew, M., & Slaney, E. (2024). Bilateral Optic Neuropathy Secondary to Intravenous Carboplatin Therapy. *Journal of Ophthalmic and Vision Research (JOVR)*, 133–136.
- Mathew, D. J., Arthur, A., & John, S. S. (2017). Presumed chemotherapy-induced optic neuropathy and maculopathy: a case report. *The Open Ophthalmology Journal*, 11, 298.
- L. D., & Janoff, A. S. (2007). Optimizing combination chemotherapy by controlling drug ratios. *Molecular interventions*, 7(4), 216.
- gh, T. P., & Kerin, M. J. (2017). Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. *Breast Cancer: Targets and Therapy*, 9, 393.



- Moon, J., Choi, S. H., Lee, M. J., Jo, D. H., Park, U. C., Yoon, S.-O., Woo, S. J., & Oh, J. Y. (2021). Ocular surface complications of local anticancer drugs for treatment of ocular tumors. *The Ocular Surface*, 19, 16–30. <https://doi.org/10.1016/j.jtos.2020.11.006>
- Morrow, M., & Khan, A. J. (2020). Locoregional management after neoadjuvant chemotherapy. *Journal of Clinical Oncology*, 38(20), 2281.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia. V1 2017. Available at: <http://www.nccn.org>. Diakses 31 Maret 2022.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines for Acute Myeloid Leukemia. V1 2018. Available at: <http://www.nccn.org>. Diakses 31 Maret 2022.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines for Chronic Myeloid Leukemia. V2 2020. Available at: <http://www.nccn.org>. Diakses 31 Maret 2022
- Nurgali, K., Jagoe, R. T., & Abalo, R. (2018). Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?. *Frontiers in pharmacology*, 9, 245.
- Omoti AE, Omoti CE. (2006). Ocular toxicity of systemic anticancer chemotherapy. *Pharmacy Practice*, 4(2), 55-59.
- Papaccio, F., Roselló, S., Huerta, M., Gambardella, V., Tarazona, N., Fleitas, T., ... & Cervantes, A. (2020). Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. *Cancers*, 12(12), 3611.
- Park, J., Kim, J., & Baek, S. (2019). Clinical features and treatment outcomes of patients with tearing after chemotherapy. *Eye*, 33(5), 746–753.
- B, Jain S, Han H, Park J. Ocular surface disease associated with immune checkpoint inhibitor therapy. *Ocul Surf*. 2021 Apr;20:115–29.
- ingh and Abhishek Singh. (2012). Ocular Adverse Effect of Anti-cancer Chemotherapy and Targeted Therapy. *Journal Cancer Therapeutics and Research*



- Ponjavic, V., Gränse, L., Stigmar, E. B., & Andreasson, S. (2004). Reduced full-field electroretinogram (ERG) in a patient treated with methotrexate. *Acta Ophthalmologica Scandinavica*, 82(1), 96-99.
- Prensky, C. J., Brissette, A. R., Sippel, K. C., & Teitelbaum, A. (2018). Eye symptoms and toxicities of systemic chemotherapy. *The MASCC Textbook of Cancer Supportive Care and Survivorship*, 563–583.
- Qian, L., & Wei, W. (2022). Identified risk factors for dry eye syndrome: A systematic review and meta-analysis. *PLOS ONE*, 17(8), e0271267. <https://doi.org/10.1371/journal.pone.0271267>
- Rajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A., & Bokemeyer, C. (2016). Testicular germ cell tumours. *The Lancet*, 387(10029), 1762-1774.
- Rakotonjanahary J, Gravier N, Lambron J, De Carli E, Toulgoat F, Delion M, et al. Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort. Ammann RA, editor. *PLOS ONE*. 2019 Mar 8;14(3):e0212107.
- Rao R, Honavar SG, Reddy VP. Preservation of retinoblastoma group E eyes with neovascular glaucoma using intravenous chemotherapy: risk factors and outcomes. *Br J Ophthalmol*. 2019 Feb 22;bjophthalmol-2018-313442.
- Rzeszotarska A, Stodolska-Nowak A, Kufel-Grabowska J, Nowakowski B, Kocięcki J. Ocular side effects of the taxane-based chemotherapy—do only vascular disorders matter? *OncoReview*. 2019;9(3 (35)):59–63.
- Sabaner MC. Treatment of Intravitreal Ranibizumab Resistant Radiation Retinopathy with Intravitreal Dexamethasone Implant: A Case Report. *Beyoglu Eye J* [Internet]. 2022 [cited 2024 Mar 13]; Available from: https://jag.journalagent.com/beyoglu/pdfs/BEJ_7_4_324_328.pdf
- le-Viteri, M., & Cudrnak, T. (2019). Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib. *Leukemia & Lymphoma*, 60(3), 842-844.



- Sajith, M., Pawar, A., Bafna, V., Bartakke, S., Subramanian, K., & Vaidya, N. (2020). Serum methotrexate level and side effects of high dose methotrexate infusion in pediatric patients with acute lymphoblastic leukaemia (ALL). *Indian Journal of Hematology and Blood Transfusion*, 36(1), 51-58.
- Shen, C. J., Kry, S. F., Buchsbaum, J. C., Milano, M. T., Inskip, P. D., Ulin, K., Francis, J. H., Wilson, M. W., Whelan, K. F., & Mayo, C. S. (2023). Retinopathy, optic neuropathy, and cataract in childhood cancer survivors treated with radiation therapy: A PENTEC comprehensive review. *International Journal of Radiation Oncology* Biology* Physics*.
- Shin, E., Chung, T.Y., Han, J. S., Lim, D. H.. (2018). Corneal subepithelial changes and prognosis after chemotherapy using Epidermal or Fibroblast growth factor receptor inhibitor, 59, 3840.
- Shin E, Lim DH, Han J, Nam DH, Park K, Ahn MJ, et al. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. *BMC Ophthalmol*. 2020;20:1–13.
- Simonett, J. M., Ambady, P., Neuwelt, E. A., Skalet, A. H., & Lin, P. (2020). Maculopathy Associated With Osmotic Blood–Brain Barrier Disruption and Chemotherapy in Patients With Primary CNS Lymphoma. *Ophthalmic Surgery, Lasers and Imaging Retina*, 51(5), S5-S12.
- Sodhi M, Yeung SN, Maberley D, Mikelberg F, Etminan M. Risk of ocular adverse events with taxane-based chemotherapy. *JAMA Ophthalmol*. 2022;140(9):880–4.
- Soni, M., Walia, S., & Jain, P. (2023). Dry eye disease in head and neck cancer patients undergoing radiotherapy. *Indian Journal of Ophthalmology*, 71(4), 1556–1560. https://doi.org/10.4103/IJO.IJO_2673_22
- Monteiro de Araújo D, Brito R, Pereira-Figueiredo D, dos Santos-Rodrigues A, De Logu F, Nassini R, Zin A, Calaza KC. (2022). Retinal Toxicity Induced by Chemical Agents. *International Journal of Molecular Sciences*, 23(15),8182.



- Stache, N., Bohn, S., Sperlich, K., George, C., Winter, K., Schaub, F., Do, H.-V., Röhlig, M., Reichert, K.-M., & Allgeier, S. (2023). Taxane-Induced Neuropathy and Its Ocular Effects—A Longitudinal Follow-up Study in Breast Cancer Patients. *Cancers*, 15(9), 2444.
- Stoicescu, E. A., Burcea, M., Iancu, R. C., Zivari, M., Popa Cherecheanu, A., Bujor, I. A., Rastoaca, C., & Iancu, G. (2021). Docetaxel for breast cancer treatment-side effects on ocular surface, a systematic review. *Processes*, 9(7), 1086.
- Sudoyo, Aru W, dkk. Buku Ajar Ilmu Penyakit Dalam. Jilid III Edisi IV. Jakarta: Interna Publishing Pusat Penerbitan Ilmu Penyakit Dalam
- Sugiyama M, Terashita Y, Hara K, Cho Y, Iguchi A, Chin S, et al. Corticosteroid-induced glaucoma in pediatric patients with hematological malignancies. *Pediatr Blood Cancer*. 2019 Dec;66(12):e27977.
- Takada Y, Sumioka T, Tamura T, Saika S. A Glaucoma Patient with an Intraocular Pressure Decrease following Total Gastrectomy and Postoperative Anticancer Treatment. Chen HY, editor. *Case Rep Ophthalmol Med*. 2023 Feb 14;2023:1–4.
- Thatte S, Monga A, Goyal Y. A Clinical Study of Intensity-Modulated Radiotherapy-Induced Dry Eye Disease in Head and Neck Malignancies. 2022.
- Totadri, S., & Trehan, A. (2016). Vincristine induced cortical blindness: an alarming but reversible side effect. *Pediatr Hematol Oncol J*, 1(3), 61-62.
- Uwineza, A., Kalligeraki, A. A., Hamada, N., Jarrin, M., & Quinlan, R. A. (2019). Cataractogenic load—A concept to study the contribution of ionizing radiation to accelerated aging in the eye lens. *Mutation Research/Reviews in Mutation Research*, 779, 68–81.
- iva, Vishnu, Jovita. (2021). Evaluation of Ocular Status in Patients Undergoing Combination Cancer Chemotherapy. *European Journal of Molecular and Clinical Medicine*, 8(4).



- Vishnevskia-Dai V, Rozner L, Berger R, Jaron Z, Elyashiv S, Markel G, et al. Ocular side effects of novel anti-cancer biological therapies. *Sci Rep*. 2021;11(1):787.
- Wang F, Ferrante S, Maiese EM, Willson J, Chen CC, Nunna S, et al. Real-World Incidence and Clinical and Economic Burden of Managing Ocular Events in Patients with Active Multiple Myeloma. *Blood*. 2020 Nov 5;136(Supplement 1):15–6.
- Wang X, Yang Y, An Y, Fang G. The mechanism of anticancer action and potential clinical use of kaempferol in the treatment of breast cancer. *Biomedicine & Pharmacotherapy*. 2019 Sep 1;117:109086.
- Warkad V, Tripathy D. Intravitreal chemotherapy-induced cataract in retinoblastoma: challenges and outcome. *BMJ Case Rep*. 2022 Dec;15(12):e250617.
- Ye, Y.-T., Zhou, Z.-Y., Wen, L.-S., Sun, Y., Chu, Z.-J., & Dou, G.-R. (2022). The significance of the ocular adverse effect induced by systemic taxane application. *Frontiers in Bioscience-Landmark*, 27(6), 171.
- Young L, Finnigan S, Streicher H, Chen HX, Murray J, Sen HN, et al. Ocular adverse events in PD-1 and PD-L1 inhibitors. *J Immunother Cancer*. 2021;9(7).
- Yuan X, Feng Y, Li D, Li M. Unilateral visual impairment in a patient undergoing chemotherapy: a case report and clinical findings. *BMC Ophthalmol*. 2019 Dec;19(1):236.
- Zahler, S., Ghazi, N. G., & Singh, A. D. (2019). Principles and complications of chemotherapy. *Clinical Ophthalmic Oncology: Basic Principles*, 129–142.
- Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. (2019). Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. *International Journal of Molecular Sciences*, 20(6),1451.
- Y, Cheng JY, Xu H, Fang ZB, Chen X, Qiu SY, Sun XH, Lee RK, Xiao M, Kong XM. Mean amplitude of intraocular pressure excursions: a new assessment parameter for 24-h pressure fluctuations in glaucoma patients. *Eye (Lond)* 2021;35(1):326–333.



Zheng J, Chen W, Huang D, Wang Y, Zheng D, Zhou L, et al. Ocular symptoms as the initial clinical manifestations in patients with extraocular tumors. *Ann Transl Med.* 2021;9(6).



Optimized using
trial version
www.balesio.com